Key Highlights:
• Insilico Medicine’s AI-driven drug discovery platform Pharma.AI enabled rapid development of Rentosertib, a novel TNIK inhibitor showing promising Phase IIa clinical results for IPF.
• Phase IIa trial demonstrated a dose-dependent improvement in lung function with 60 mg QD Rentosertib increasing forced vital capacity (FVC) by +98.4 mL versus placebo decline of -20.3 mL.
• Biomarker analyses validated Rentosertib’s anti-fibrotic and anti-inflammatory mechanisms, reinforcing AI’s role in identifying novel drug targets and accelerating clinical success.
AI-Powered Discovery Accelerates Rentosertib from Concept to Clinical Validation
Insilico Medicine leveraged its proprietary generative AI platform, Pharma.AI, to identify and design Rentosertib (ISM001-055), targeting the novel kinase TNIK implicated in fibrosis progression in IPF. This AI-driven approach compressed traditional drug discovery timelines from years to just 12–18 months, demonstrating unprecedented efficiency and precision in candidate nomination and preclinical success. Rentosertib’s recent Phase IIa clinical validation marks one of the first proof-of-concept successes for AI-discovered therapeutics in biopharma.
Promising Clinical Data Signals Potential Breakthrough for IPF Patients
The GENESIS-IPF Phase IIa study, a double-blind placebo-controlled trial involving 71 patients, revealed that Rentosertib has a manageable safety profile with mostly mild to moderate adverse events. The 60 mg once-daily dose produced the most significant lung function improvements, measured by forced vital capacity (FVC), with a mean increase of +98.4 mL over 12 weeks compared to a decline in the placebo group. These encouraging outcomes highlight Rentosertib’s promise as a disease-modifying therapy for a condition with limited treatment options.
Biomarker Insights Validate Mechanism and Guide Future Development
Exploratory biomarker analysis showed dose- and time-dependent changes in serum protein profiles consistent with anti-fibrotic and anti-inflammatory effects. Notably, profibrotic proteins COL1A1, MMP10, and FAP were significantly reduced, while the anti-inflammatory cytokine IL-10 increased in high-dose groups. These molecular changes correlated with improved lung function, offering a predictive biomarker framework to optimize dosing strategies and patient selection in subsequent trials.
Paving the Way for AI-Driven Drug Discovery in Biopharma’s Future
The success of Rentosertib underscores the transformative potential of AI technologies in revolutionizing drug research and development. By integrating cutting-edge AI with automation, Insilico Medicine is setting new benchmarks for speed, efficiency, and innovation in targeting complex diseases like IPF. The company is actively engaging with regulatory agencies to advance Rentosertib into larger clinical trials, exemplifying how AI can accelerate access to novel therapies addressing unmet medical needs.
By
